Events

Date	Title
11/06/24 - 11/10/24	Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Register here Supporting Material Oncology SITC Poster 914.2 KB ActivMab SITC Poster 1.5 MB
10/29/24 - 11/01/24	17TH Clinical Trials on Alzheimer’s Disease (CTAD) Register here Supporting Material CTAD 2024_Pepinemab for VCNX Presentation 2.9 MB
09/08/24 - 09/11/24	CRI-ENCI Eighth International Cancer Immunotherapy Conference (CICON): Translating Science into Survival Register here Supporting Material CRI-ENCI Eighth International Cancer Immunotherapy Conference (CICON): Translating Science into Survival Presentation 1.1 MB
07/28/24 - 08/01/24	Alzheimer's Association International Conference® (AAIC) Register here Supporting Material Alzheimer's Association International Conference® (AAIC) Presentation 1.6 MB
05/31/24 - 06/04/24	2024 ASCO Annual Meeting Register here Supporting Material ASCO Conference Presentation 1.9 MB
05/21/24 - 05/23/24	New York Academy of Sciences, Frontiers in Cancer Immunotherapy 2024 Register here
05/13/24 - 05/17/24	PEGS Boston Register here
04/23/24	12th Alzheimer’s & Parkinson’s Drug Development Summit Register here Supporting Material 12th Alzheimer’s & Parkinson’s Drug Development Summit Presentation 3.2 MB
04/15/24 - 04/17/24	Festival of Biologics Register here Supporting Material Festival of Biologics Presentation 1.6 MB
03/20/24 - 03/23/24	Society for Surgical Oncology (SSO) Annual Meeting Register here
01/18/24 - 01/20/24	ASCO Gastrointestinal Cancers Symposium Register here
12/13/23 - 12/16/23	Antibody Engineering & Therapeutics Conference Register here
11/03/23	Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Listen to webcast Supporting Material SITC Presentation 2.4 MB
10/24/23 - 10/27/23	16th Clinical Trials on Alzheimer’s Disease (CTAD) Register here Supporting Material Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in and ongoing Phase 1/2 AD study 3.1 MB
10/01/23 - 10/05/23	Keystone Symposium: B CELLS AND TERTIARY LYMPHOID STRUCTURES: EMERGING TARGETS IN CANCER THERAPEUTICS Register here Supporting Material Keystone Symposium: B cells and TLS_POSTER 2.6 MB
09/27/23 - 09/30/23	AACR SPECIAL CONFERENCE IN CANCER RESEARCH: PANCREATIC CANCER Register here Supporting Material AACR SPECIAL CONFERENCE IN CANCER RESEARCH: PANCREATIC CANCER 1.6 MB
09/25/23 - 09/28/23	20th Discovery on Target Register here Supporting Material DOT2023poster 1.8 MB DOT2023presentation 5.6 MB
06/09/23 at 10:00 AM EDT	Jefferies Healthcare Conference
06/05/23 - 06/08/23	BIO International Convention
06/02/23 - 06/06/23	ASCO 2023 Annual Meeting Supporting Material ASCO Poster - PDAC study abstract # TPS4195 2.3 MB
05/15/23 - 05/16/23	PEGS Boston Summit Supporting Material PEGS Boston 2023. Native complex membrane antigen expression on poxvirus for antibody discovery 2.1 MB
03/23/23 - 03/24/23	AAIC Advancements: Immunity Supporting Material AAIC Advancements: Immunity Presentation 3.8 MB
03/22/23 - 03/25/23	SSO 2023 Society of Surgical Oncology Annual Meeting
12/04/22 - 10/08/22	Antibody Engineering and Therapeutics
11/29/22 - 12/02/22	15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference More information Supporting Material CTAD 2022 poster LP-19: Pepinemab is a novel potential treatment for neurodegenerative disease 2.6 MB Antibody Engineering and Therapeutics 2022 poster: ActivMAb - native complex membrane antigen expression for antibody discovery 3.2 MB
11/10/22 - 11/12/22	Society for Immunotherapy of Cancer (SITC), 37th Annual Meeting Supporting Material Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma 8.1 MB Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC) 3 MB “Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma” presented by Dr. Brian Olson of Emory University Friday Nov 11, 4:20-5:35 “Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC)” poster presentation by Dr. Hyo Han of Moffitt Cancer Center Nov 10 - 11, 9:00 am - 9:00 pm
11/03/22 - 11/05/22	29th Annual Meeting of the Huntington Study Group Supporting Material HSG Highlight: SIGNAL Trial Results 2.7 MB "HSG Highlight: SIGNAL Trial Results” presented by Dr. Maurice Zauderer and Dr. Andrew Feigin Friday Nov 4, 10:15-10:45
09/16/22 - 09/18/22	European Huntington's Disease Network EHDN2022 Plenary Meeting Supporting Material Synthesis of key results and conclusions of the SIGNAL phase 2 study of pepinemab as a treatment for early HD 2.7 MB
09/09/22 - 09/13/22	ESMO Congress 2022 Supporting Material Neoadjuvant Pepinemab in Combination with Nivolumab and/or Ipilimumab in Resectable Stage III Melanoma 1.1 MB
07/31/22 - 08/01/22	Alzheimer's Association International Conference (AAIC) 2022 Supporting Material Corporate Presentation 3.4 MB Watch video presentation
06/13/22 - 06/16/22	BIO International Convention
06/08/22 - 06/10/22	Jefferies Healthcare Conference Supporting Material Corporate Presentation 3.4 MB
06/03/22 - 06/07/22	2022 ASCO Annual Meeting
05/02/22 - 05/03/22	PEGS Boston
04/08/22 - 04/13/22	AACR ANNUAL MEETING 2022 Supporting Material AACR Annual Meeting 2022 poster: Phase 1/2 study of pepinemab with pembrolizumab for first-line treatment of R/M Head and Neck Cancer 1.9 MB AACR Annual Meeting 2022 poster: Phase 1/2 study of pepinemab with pembrolizuma…
03/28/22 - 03/31/22	BIO Europe 2022
02/28/22 - 03/03/22	17th Annual HD Therapeutics Conference Supporting Material 2022 CHDI poster: Combination anti-SEMA4D immunotherapy and HTT-lowering ASO provide benefit beyond either individual therapy in preclinical HD mouse model 5.9 MB
02/24/22 - 02/26/22	2022 Multidisciplinary Head And Neck Cancers Symposium Supporting Material 2022 HNSCC Symposium Poster: Phase 1/2 study of pepinemab in combination with pembrolizumab as first-line treatment of advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84) 1.6 MB
01/05/22 - 01/07/22	LifeSci Partners Corporate Access Event Supporting Material Corporate Presentation 4.6 MB
11/30/21 - 12/01/21	Head and Neck Cancer Drug Development Summit
11/18/21 at 8:00 AM GMT	Jefferies London Healthcare Conference Supporting Material Corporate Presentation 4 MB Maurice Zauderer, CEO will present. More Information
11/12/21 at 7:00 AM EST to 11/13/21 at 8:30 PM EST	Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 Supporting Material SITC 2021 poster: Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84) 10.7 MB More Information
11/09/21 - 11/12/21	Clinical Trials on Alzheimer's Disease conference (CTAD) Supporting Material Agenda 5.1 MB CTAD 2021 presentation: SEMA4D blocking antibody, pepinemab , is a novel potential treatment for neurodegenerative disease: clinical proof of concept in HD supports clinical development in AD 2.8 MB More Information
11/05/21 from 3:15 PM EDT to 11/06/21	HSG 2021: UNMASKING HD. The 28th Annual Meeting of the Huntington Study Group Supporting Material Watch video presentation Pepinemab – Anti-SEMA4D Antibody Treatment for Huntington’s Disease 2.3 MB
09/20/21 - 09/23/21	Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Supporting Material Corporate Presentation 4.7 MB Elizabeth Evans COO will present.
09/09/21 - 09/11/21	EHDN2021 Annual Meeting
08/25/21 - 08/27/21	World Orphan Drug Congress USA 2021
07/05/21 - 07/09/21	XV European Meeting on Glial Cells in Health and Disease Elizabeth Evans, SVP Discovery and Translational Medicine, will present. Program
06/14/21 - 06/18/21	BIO Digital International Convention
06/10/21 - 06/11/21	BIO Digital International Convention
06/01/21 - 06/04/21	2021 Jefferies Virtual Healthcare Conference Supporting Material Corporate Presentation 4.9 MB
04/27/21 - 04/29/21	16th Annual HD Therapeutics Conference Supporting Material Zauderer - Pepinemab SEMA4D Antibody: Potential Treatment for Neurodegenerative Disease 958.2 KB Poster - SEMA4D upregulation signals neuronal stress and triggers reactive astrogliosis 1.8 MB Poster - Results of phase 2 SIGNAL trial of the SEMA4D blocking antibody 1.3 MB Program
03/16/21 at 2:30 PM EDT	Oppenheimer 31st Annual Healthcare Conference Listen to webcast
03/09/21 at 2:00 AM EST	AD/PD 2021 Virtual Presentation: “Results of Phase 2 Huntington’s Disease Trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL) Will Guide Clinical Trial in Alzheimer’s Disease” Supporting Material AD/PD 2021 Presentation 2.2 MB
01/06/21 at 11:00 AM EST	10th Annual LifeSci Partners Corporate Access Event Listen to presentation
10/30/20 at 10:00 AM EDT	Huntington Study Group 2020 Medical Conference
10/27/20 at 10:00 AM EDT	Virtual Investor KOL Roundtable Watch video webcast
06/16/20 at 10:00 AM EDT	Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex will present at the Virtual Investor Fireside Chat Series Replay of Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex presenting at the Virtual Investor Fireside Chat Series (click here) Virtual Investor Fireside Chat Series
09/24/19 at 1:30 PM EDT	Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference Supporting Material Vaccinex Presentation at the Ladenburg Thalmann 2019 Healthcare Conference September 24, 2019 5.1 MB
06/03/19 at 2:15 PM EDT	ASCO Annual Meeting: Pilot Integrated Biomarker Study of VX15/2503 in Combination with Ipilimumab and/or Nivolumab in Patients with Resectable Metastatic Melanoma
06/01/19 at 9:00 AM EDT	ASCO Annual Meeting: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
04/01/19 at 1:00 PM EDT	ASCO Annual Meeting: Vaccinex, Inc. - Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
04/01/19 at 8:00 AM EDT	AACR 2019 Meeting: Vaccinex, Inc. - Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies
03/31/19 at 1:00 PM EDT	AACR 2019 Meeting: Vaccinex, Inc. - Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
03/19/19 at 3:55 PM EDT	Vaccinex, Inc. at the Oppenheimer & Co.’s 29th Annual Healthcare Conference
03/12/19 at 4:00 PM EDT	Q4 2018 Vaccinex, Inc. Earnings Release
01/18/19 at 12:00 PM EST	Vaccinex, Inc. at the PEPTALK: Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier
11/16/18 at 12:00 PM EST	Vaccinex, Inc. at the 2018 Huntington’s Study Group (HSG) Annual Meeting
11/13/18 at 8:30 AM EST	Q3 2018 Vaccinex, Inc. Earnings Release
11/09/18 at 12:00 PM EST to 11/10/18 at 11:59 PM EST	Vaccinex, Inc. at the Annual Conference of the Society of Immunotherapy for Cancer Supporting Material Poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 4.2 MB Podium Presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 4.8 MB
10/25/18 at 12:00 PM EDT	Vaccinex, Inc. at the BTIG Healthcare Conference
10/04/18 at 12:00 PM EDT	Vaccinex, Inc. at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
10/02/18 at 8:30 AM EDT	Vaccinex, Inc. at the Ladenburg Thalmann 4th Annual Healthcare Conference Click here for webcast
09/30/18 at 11:45 AM EDT	Vaccinex, Inc. at the International Cancer Immunotherapy Conference